tacrolimus has been researched along with Hyperpigmentation* in 9 studies
1 review(s) available for tacrolimus and Hyperpigmentation
Article | Year |
---|---|
Diltiazem-associated photodistributed hyperpigmentation: report of two Japanese cases and published work review.
Scherschum et al. proposed diltiazem-associated photodistributed hyperpigmentation as a novel type of drug-induced photosensitive lichenoid eruption. The characteristic clinical features were slate-gray reticulated hyperpigmentation on sun-exposed areas, while lichenoid dermatitis with prominent pigmentary incontinence was noted histologically. Although the clinical and histological features were similar to those of lichen planus pigmentosus, the histological features did not show either compact hyperkeratosis or wedge-shaped hypergranulosis, which are typical histological features of lichen planus. We describe two Japanese cases of diltiazem-associated photodistributed hyperpigmentation, who were successfully treated with topical tacrolimus, and review the published work. Topics: Aged, 80 and over; Asian People; Calcium Channel Blockers; Diltiazem; Drug Eruptions; Female; Humans; Hyperpigmentation; Japan; Photosensitivity Disorders; Tacrolimus; Treatment Outcome | 2010 |
8 other study(ies) available for tacrolimus and Hyperpigmentation
Article | Year |
---|---|
Acute Onset Linear Lichen Planus Pigmentosus of the Forehead: A Case Series.
Linear lichen planus pigmentosus (LPP) of the face is a rare variant of lichen planus, with only a few cases published in the literature.1 It is an inflammatory condition with unknown etiology, characterized by blue-gray hyperpigmented macules, and tends to affect sun-exposed areas of the head and neck.1-4 The pathophysiology of linear lichen pigmentosus is poorly understood, though it is postulated to be caused by T-lymphocyte autoimmunity against keratinocytes.5-7 LPP more frequently affects middle age woman and skin phototypes III-VI.1,3 Treatment for linear LPP is difficult and there is no established first-line therapy; however, tacrolimus ointment, topical corticosteroids, and various systemic agents have shown to be effective in improving the appearance.3,8,9 Prior reports have characterized linear LPP that follows the lines of Blashko as more commonly affecting the trunk.1 We present three cases of linear lichen planus pigmentosus (LPP) of the forehead, a unique novel presentation of linear LPP of the face. One of our cases also provides supporting evidence for tacrolimus to be used as a preferred therapy to treat linear LPP of the face; however, more research is needed to support this claim. To our knowledge, this case series is the largest case series of linear lichen planus pigmentosus (LPP) of the forehead to be reported. J Drugs Dermatol. 2023;22(1):94-97. doi:10.36849/JDD.7200. Topics: Female; Forehead; Humans; Hyperpigmentation; Lichen Planus; Middle Aged; Skin; Tacrolimus | 2023 |
532 nm Q-switched laser for the treatment of hyperpigmentation induced by topical tacrolimus.
Topics: Humans; Hyperpigmentation; Immunosuppressive Agents; Lasers, Solid-State; Tacrolimus; Treatment Outcome | 2020 |
Diltiazem-associated Photodistributed Hyperpigmentation.
Diltiazem is a calcium-channel blocker commonly used for the treatment of hypertension. Common adverse effects include dizziness, headache, and edema. Fewer than 20 cases of diltiazem-associated photodistributed hyperpigmentation have been reported in the literature. Here, we present the case of a 71-year-old woman with new-onset facial hyperpigmentation 6 months after initiating treatment with diltiazem. Topics: Aged; Biopsy; Calcium Channel Blockers; Dermatologic Agents; Diltiazem; Female; Humans; Hyperpigmentation; Hypertension; Ointments; Photosensitivity Disorders; Skin; Tacrolimus; Treatment Outcome; Withholding Treatment | 2020 |
Comparison between the efficacy of microneedling combined with 5-fluorouracil vs microneedling with tacrolimus in the treatment of vitiligo.
Several treatment modalities had been used for the treatment of vitiligo, but the optimal treatment has not yet been identified.. To study the efficacy of microneedling with 5-flurouracil vs its efficacy with tacrolimus in the treatment of vitiligo.. Twenty-five patients with vitiligo were subjected to microneedling of 2 patches of vitiligo with dermapen, then application of 5-fluorouracil to 1 patch and tacrolimus on the other patch. This procedure was repeated every 2 weeks for every patient for maximum 6 months (12 sessions). The patients were followed up for 3 months after the last session.. The overall repigmentation was significantly higher in 5-fluorouracil-treated patches compared with tacrolimus. Excellent improvement occurred in 48% of 5- flurouracil-treated patches while only in 16% of tacrolimus-treated patches. In the acral parts, 40% of the patches treated with 5-fluorouracil achieved excellent improvement (repigmentation >75%), while no patch in the acral parts achieved excellent improvement with tacrolimus. However, there was significant difference between the 2 drugs,regarding inflammation, ulceration, and hyperpigmentation which occurred with 5-fluorouracil.. Microneedling combined with 5-fluorouracil or tacrolimus is safe and effective treatment of vitiligo. However, 5-fluorouracil achieved a greater percentage of repigmentation than tacrolimus particularly in the acral parts. Topics: Administration, Cutaneous; Cosmetic Techniques; Dermatologic Agents; Female; Fluorouracil; Humans; Hyperpigmentation; Immunosuppressive Agents; Inflammation; Male; Needles; Occlusive Dressings; Skin Ulcer; Tacrolimus; Treatment Outcome; Vitiligo; Young Adult | 2018 |
Acquired Hyperpigmentation and Cicatricial Alopecia.
Topics: Aged; Alopecia; Chloroquine; Diagnosis, Differential; Female; Humans; Hyperpigmentation; Lichen Planus; Tacrolimus; Treatment Outcome | 2016 |
Acquired Bilateral Dyspigmentation on Face and Neck: Clinically Appropriate Approaches.
Facial dyspigmentation in Asian women often poses diagnostic and therapeutic challenges. Recently, a distinctive bilateral hyperpigmentation of face and neck has occasionally been observed. This study was performed to investigate the clinico-pathological features of this dyspigmentation as well as proper treatment approaches. We retrospectively investigated the medical records including photographs, routine laboratory tests, histopathologic studies of both lesional and peri-lesional normal skin and patch test of thirty-one patients presented acquired bizarre hyperpigmentation on face and neck. The mean age of patients was 52.3 years and the mean duration of dyspigmentation was 24.2 months. In histologic evaluations of lesional skin, a significantly increased liquefactive degeneration of basal layer, pigmentary incontinence and lymphocytic infiltration were noted, whereas epidermal melanin or solar elastosis showed no statistical differences. Among 19 patients managed with a step-by-step approach, seven improved with using only topical anti-inflammatory agents and moisturizer, and 12 patients gained clinical benefit after laser therapy without clinical aggravation. Both clinical and histopathologic findings of the cases suggest a distinctive acquired hyperpigmentary disorder related with subclinical inflammation. Proper step-by-step evaluation and management of underlying subclinical inflammation would provide clinical benefit. Topics: Administration, Topical; Adult; Anti-Inflammatory Agents; Face; Female; Humans; Hyperpigmentation; Laser Therapy; Male; Melanosis; Middle Aged; Neck; Patch Tests; Photography; Retrospective Studies; Skin; Tacrolimus; Young Adult | 2016 |
Mucosal pigmentation after oral lichen planus treatment with topical tacrolimus.
Erosive oral lichen planus (OLP) is a painful chronic inflammatory disease that is sometimes resistant to systemic or topical therapies. Topical steroids remain the mainstay of therapy, but topical tacrolimus has recently been used to treat OLP resistant to topical corticosteroids. Topical tacrolimus appears as an effective and safe treatment of symptomatic OLP. We report the first histopathologically documented case of oral mucosa pigmentation after OLP treatment with topical tacrolimus. The relation between tacrolimus treatment and staining was suggested by the appearance of pigmentation during topical tacrolimus treatment and its clinical disappearance when treatment was stopped. Histopathology showed an increase in melanocyte numbers and melanogenesis. Topics: Administration, Cutaneous; Aged; Diagnosis, Differential; Female; Humans; Hyperpigmentation; Immunosuppressive Agents; Lichen Planus, Oral; Mouth Diseases; Mouth Mucosa; Tacrolimus | 2005 |
Tacrolimus ointment in the treatment of dirty neck lesions in atopic dermatitis.
Topics: Adolescent; Adult; Dermatitis, Atopic; Female; Humans; Hyperpigmentation; Immunosuppressive Agents; Male; Neck; Ointments; Tacrolimus | 2005 |